The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of CDK4/6 inhibitors after progression on CDK4/6 inhibitor in patients with hormone receptor-positive/HER2-negative advanced breast cancer.